- Home
- SER vs PRT Comparison
SER vs PRT Comparison
Compare SER & PRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SER
- PRT
- Stock Information
- Founded
- SER 2017
- PRT 2017
- Country
- SER United States
- PRT United States
- Employees
- SER N/A
- PRT N/A
- Industry
- SER Biotechnology: Pharmaceutical Preparations
- PRT Oil & Gas Production
- Sector
- SER Health Care
- PRT Energy
- Exchange
- SER Nasdaq
- PRT Nasdaq
- Market Cap
- SER 53.5M
- PRT N/A
- IPO Year
- SER 2018
- PRT N/A
- Fundamental
- Price
- SER $5.75
- PRT $3.82
- Analyst Decision
- SER Strong Buy
- PRT
- Analyst Count
- SER 1
- PRT 0
- Target Price
- SER $11.00
- PRT N/A
- AVG Volume (30 Days)
- SER 12.0K
- PRT 29.0K
- Earning Date
- SER 05-24-2025
- PRT 05-20-2025
- Dividend Yield
- SER N/A
- PRT 11.67%
- EPS Growth
- SER N/A
- PRT N/A
- EPS
- SER N/A
- PRT 0.42
- Revenue
- SER $56,000.00
- PRT $6,018,264.00
- Revenue This Year
- SER N/A
- PRT N/A
- Revenue Next Year
- SER N/A
- PRT N/A
- P/E Ratio
- SER N/A
- PRT $8.91
- Revenue Growth
- SER N/A
- PRT N/A
- 52 Week Low
- SER $3.81
- PRT $3.26
- 52 Week High
- SER $14.57
- PRT $4.63
- Technical
- Relative Strength Index (RSI)
- SER 54.32
- PRT 45.44
- Support Level
- SER $5.64
- PRT $3.73
- Resistance Level
- SER $6.61
- PRT $3.87
- Average True Range (ATR)
- SER 0.48
- PRT 0.11
- MACD
- SER -0.02
- PRT -0.00
- Stochastic Oscillator
- SER 53.51
- PRT 34.18
About SER Serina Therapeutics Inc.
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The Company has one reportable segment relating to the research and development of its POZ platform.